RZLT vs SCYX

Rezolute, Inc. vs SCYNEXIS, Inc. — Valuation Comparison 2026

RZLT

Pharmaceutical Preparations
Rezolute, Inc.
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$3.30
Last close
Models
7/13
Active
VS

SCYX

Pharmaceutical Preparations
SCYNEXIS, Inc.
Quality
5.6
out of 10
Value Trap
30
LOW
Price
$0.70
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType RZLT Fair ValueRZLT Upside SCYX Fair ValueSCYX Upside
Bayesian DCF Intrinsic $0.91 -72.4% $0.38 -46.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.46 -55.6% $0.84 +19.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RZLT vs SCYX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RZLT vs SCYX — Which Stock Is More Undervalued?

SCYX scores higher with a 5.6/10 quality rating vs RZLT's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rezolute, Inc. (RZLT) and SCYNEXIS, Inc. (SCYX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RZLT currently trades at $3.30 with a QOC of 4.0/10, while SCYX trades at $0.70 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).